Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO

被引：1
|
作者：
Pauligk, Claudia
Tannapfel, Andrea
Meiler, Johannes
Luley, Kim Barbara
Kopp, Hans-Georg
Homann, Nils
Hofheinz, Ralf Dieter
Schmalenberg, Harald
Probst, Stephan
Haag, Georg Martin
Egger, Matthias
Behringer, Dirk M.
Stoehlmacher, Jan
Prasnikar, Nicole
Block, Andreas
Trojan, Jorg
Koenigsmann, Michael
Schmiegel, Wolff
Jaeger, Elke
Al-Batran, Salah-Eddin
机构：
[1] Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany
[2] Ruhr Univ Bochum, Inst Pathol, Bochum, Germany
[3] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany
[4] UKSH Campus Luebeck, Lubeck, Germany
[5] Univ Hosp, Med Ctr 2, Tubingen, Germany
[6] Acad Teaching Hosp Wolfsburg, Dept Internal Med 2, Wolfsburg, Germany
[7] Univ Med Ctr Mannheim, Dept Hematol & Med Oncol, Mannheim, Germany
[8] Univ Klinikum Jena, Jena, Germany
[9] Klinikum Bielefeld, Bielefeld, Germany
[10] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany
[11] Ortenau Klinikum Lahr, Lahr, Germany
[12] Augusta Kranken Anstalt, Bochum, Germany
[13] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[14] Klinikum Ludwigsburg, Ludwigsburg, Germany
[15] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[16] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany
[17] MediProjekt, Hannover, Germany
[18] Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Internal Med, Bochum, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.4016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4016
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation
    Amodeo, Salvatore
    Masi, Antonio
    Melis, Marcovalerio
    Ryan, Theresa
    Hochster, Howard S.
    Cohen, Deirdre J.
    Chandra, Anurag
    Pachter, H. Leon
    Newman, Elliot
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (05) : 922 - 935
  • [22] Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
    Glatz, Torben
    Verst, Rasmus
    Kuvendjiska, Jasmina
    Bronsert, Peter
    Becker, Heiko
    Hoeppner, Jens
    Kulemann, Birte
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (08) : 1 - 14
  • [23] SUMMARY OF THE AIO 7/90 PROTOCOL - RANDOMIZED PHASE-222 STUDY WITH ELF (ETOPOSIDE/5-FU/LEUCOVORIN) VERSUS 5-FU INFUSION/CISPLATIN VERSUS FAMTX (METHOTREXATE/5-FU/ADRIAMYCIN) IN ADVANCED STOMACH-CANCER
    WILS, J
    WILKE, H
    ROUGIER, P
    PREUSSER, P
    LACAVE, A
    ONKOLOGIE, 1992, 15 (01): : 71 - 72
  • [24] Phase II trial of oxaliplatin, 5-FU, and leucovorin chemotherapy for the previously treated patients with advanced gastric cancer
    Oh, S. C.
    Kim, Y.
    Kim, J.
    Choi, I.
    Sung, H.
    Seo, H.
    Shin, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy
    Choi, In Sil
    Kim, Ki Hwan
    Lee, Ju Hyun
    Suh, Koung Jin
    Kim, Ji-Won
    Park, Jin Hyun
    Kim, Yu Jung
    Kim, Jin-Soo
    Kim, Jee Hyun
    Kim, Jin Won
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 288 - 295
  • [26] Randomised prospective phase II study of combination chemotherapy epidoxorubicin, cisplatin, 5-FU (ECF) versus epidoxorubicin, cisplatin, capecitabin (ECX) in patients with advanced or metastatic gastric cancer
    Ocvirk, J.
    Rebersek, M.
    Skof, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment
    Kim, H
    Park, JH
    Bang, SJ
    Kim, DH
    Cho, HR
    Kim, GY
    Min, YJ
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (12) : 727 - 732
  • [28] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Fotios Loupakis
    Gianluca Masi
    Lorenzo Fornaro
    Enrico Vasile
    Giacomo Allegrini
    Eloise Fontana
    Cristina Granetto
    Lisa Salvatore
    Lucia Mentuccia
    Michele Andreuccetti
    Enrico Cortesi
    Marco Merlano
    Stefano Cascinu
    Alfredo Falcone
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 559 - 566
  • [29] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Loupakis, Fotios
    Masi, Gianluca
    Fornaro, Lorenzo
    Vasile, Enrico
    Allegrini, Giacomo
    Fontana, Eloise
    Granetto, Cristina
    Salvatore, Lisa
    Mentuccia, Lucia
    Andreuccetti, Michele
    Cortesi, Enrico
    Merlano, Marco
    Cascinu, Stefano
    Falcone, Alfredo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 559 - 566
  • [30] PHASE II STUDY OF DOCETAXEL AND 5-FLUOROURACIL (5-FU) WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH ADVANCED ESOPHAGEAL CANCER
    Hihara, J.
    Hamai, Y.
    Emi, M.
    Aoki, Y.
    Miyata, Y.
    Okada, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 238 - 238
12345